Publications
TCR T Cells
G-Rex®24 Well Plate
Publication Date: March 19, 2026
FOXM1, a transcription factor overexpressed in lung cancer but low in essential organs, can be targeted with TCR-engineered T cells. Using TCGA and GTEx data, 81% of lung adenocarcinomas and 99% of squamous tumors exceeded a 5 TPM threshold. Peptide-stimulated donor T cells recognized FOXM1 epitopes on HLA-A*02:01, HLA-A*24:02 and HLA-A*23:01, and four TCRs were cloned. The resulting TCR-T cells showed cytotoxic responses against FOXM1-expressing cell lines, released MIP-1β and IFNγ, had EC50 values of 1.4 nmol/L or lower, and showed little or no lysis of HLA-matched heart, lung, liver, kidney and brain cell lines. In NSG mice bearing H1975 FOXM1 tumors, two infusions of 10 million TCR-T1…
Publications
CAR T Cells
G-Rex®24 Well Plate
Publication Date: March 18, 2026
Among three non-signaling domain designs tested in a CD19 CAR carrying 4-1BB and IL-7Rα signaling, the IgG2.CH3/CD28 spacer–transmembrane combination gave the strongest functional performance, although CD8/CD8 produced the highest surface CAR density. The short IgG2/CD28 design showed the lowest CAR expression and weakest cytotoxicity against NALM-6 cells. IgG2.CH3/CD28 CAR T cells secreted more IFN-γ, TNF-α and IL-2 and showed the highest CD107α degranulation after NALM-6 stimulation. In repeated rechallenge with NALM-6 or Raji cells, IgG2.CH3/CD28 and CD8/CD8 CAR T cells both eliminated tumor cells. In NSG mice given 2.5 × 10⁵ NALM-6-Luc cells and 2.0 × 10⁶ CAR T cells, IgG2.CH3/CD28 ga…
Publications
Treg Cells
G-Rex®10, G-Rex®6 Well Plate
Publication Date: March 13, 2026
Engineered regulatory T cells (EngTregs) made by CRISPR-Cas9 and AAV-delivered insertion of a FOXP3 cDNA cassette into CD4+ T cells suppressed effector T cells as well as thymic Tregs, supporting their development for IPEX syndrome and possibly other autoimmune disorders. Cas9/T9 sgRNA produced an average of 90% indels at the FOXP3 locus, and LNGFR enrichment gave 90.4%–99.5% pure products across 5 studies. Seeding 4 × 10^7 enriched cells in G-Rex® flasks yielded 2 × 10^9 cells (about 50-fold). EngTregs protected mice from xenogeneic GvHD, did not blunt primary or recall antibody responses or EBV control in mouse models, and were generated from cells of five IPEX patients. They also staye…
Publications
TCR T Cells
G-Rex®24 Well Plate, G-Rex®500M, G-Rex®6 Well Plate
Publication Date: March 11, 2026
Autologous T cells engineered with an HLA-A*11:01-restricted KRAS G12V-specific TCR were tolerable in five patients with recurrent pancreatic cancer, and one patient had a complete response. In this single-arm phase 1/2 trial, patients received non-myeloablative lymphodepletion before infusion of products made by lentiviral transduction and a rapid expansion step, without IL-2 administration. Grade 3 or higher events were mainly lymphodepletion-related hematologic toxicities, with no grade 3 or higher cytokine release syndrome. The complete response lasted 5.5 months; two other patients had short-term stable disease. Retreatment gave no clinical responses, and hyper-acute rejection in som…
Publications
CAR T Cells, Treg Cells
G-Rex®24 Well Plate
Publication Date: March 5, 2026
A closed, 1 mL PDMS perfusion microbioreactor (K-MBR) expanded and lentivirally transduced primary human regulatory T cells, producing functional HLA-A2-specific CAR-Tregs. With an optimized daily feeding regime, wild-type Tregs expanded 10-fold over 12 days, matching a G-Rex® 24-well plate while using 5.1 mL of medium rather than 20 mL. In the CAR-Treg workflow, a 72-hour transduction at MOI 5 reached 67% efficiency and CAR-Treg yield rose 92% compared with a 24-well plate, with a 6-fold expansion. K-MBR-made CAR-Tregs suppressed effector T cell proliferation in an antigen-dependent manner as well as plate-made cells. Culture in the device did not alter cell viability or phenotype. All c…
Publications
Other
Publication Date: February 23, 2026
This FDA draft guidance describes how developers of individualized genetic therapies can generate evidence of safety and effectiveness under a plausible mechanism framework when randomized trials are not feasible. It centers on genome editing and antisense oligonucleotide products that target a defined genetic abnormality in very small patient populations. The agency anticipates that substantial evidence of effectiveness could come from a single adequate and well-controlled clinical investigation with confirmatory evidence, and natural history data may serve as an external control. The guidance covers nonclinical proof of concept and safety, clinical design including a lead-in baseline ob…
Publications
CAR T Cells
G-Rex®6M Well Plate
Publication Date: February 12, 2026
Third-generation CAR-T cells directed at desmoglein 2 (DSG2), a desmosomal cadherin overexpressed on epithelial-derived tumors, eliminated a wide range of solid tumors in mice without detectable toxicity to normal tissue. In vitro, the cells lysed eighteen solid tumor cell lines spanning colorectal, pancreatic, lung, prostate, breast and liver cancers. In mice, a single dose of 5x10^6 CAR-T cells cleared subcutaneous, peritoneal and lung-seeded cell-line tumors, an orthotopic AsPC-1 pancreatic model, and a patient-derived pancreatic xenograft (four of five mice). Some mice showed eventual recurrence, with residual tumor in a minority of animals. In human DSG2 transgenic mice, no overt tox…
Publications
CAR T Cells, T-Cells, TCR T Cells
G-Rex®24 Well Plate
Publication Date: February 1, 2026
Expressing constitutively active RhoA (Q63L) in human T cells increased their movement through and sampling of dense pancreatic tumor tissue without impairing expansion, viability or direct killing. CD4+ and CD8+ T cells were stimulated with anti-CD3/CD28 beads in Optimizer medium containing 30 U/mL IL-2, IL-7 and IL-15, transduced with lentivirus at MOI=20 on day 2, purified on day 4 through the RQR8 CD34 marker, and expanded three more days in a 24-well G-Rex® once purity exceeded 95%. RhoA(Q63L) cells showed about twofold higher motility coefficients in 3D collagen, four versus two carcinoma-cell interaction events per T cell as mesothelin-CAR T cells, reduced PD-1 and LAG-3, and signi…
Publications
NKT Cells
Publication Date: January 29, 2026
Allogeneic mesothelin-targeting CAR-NKT cells made from engineered cord blood stem cells killed endometrial carcinoma cells and suppressive myeloid cells while showing a favorable safety profile in mouse models. A six-week culture of lentivirus-transduced CD34+ progenitors gave products with more than 97% purity, and one cord blood unit with 1–5 × 10^6 CD34+ cells was projected to yield over 10^12 cells, roughly 1,000 to 10,000 doses. In primary patient samples, the cells outperformed conventional CAR-T cells against tumor cells and eliminated CD1d-positive macrophages and MDSCs. IL-15-armed cells eradicated tumors in xenografts, while mice showed no GvHD and minimal CRS markers. Tumors l…
Publications
CAR T Cells
G-Rex®100M, G-Rex®6 Well Plate
Publication Date: January 20, 2026
B7-H3 is an actionable CAR target in small cell lung cancer (SCLC) and thoracic SMARCA4-deficient undifferentiated tumors, and knocking c-JUN into the TRAC locus alongside a B7-H3 CAR improves CAR T cell activity in both. Of 23 cell lines, 22 expressed more than 1,000 B7-H3 molecules per cell, with a median of 2,966. TGF-β1 secreted by the SMARCA4-deficient H841 line suppressed B7-H3 CAR T cells; c-JUN co-expression limited TGF-β1-driven loss of type 1/2 cytokine gene expression and, versus CAR T cells without c-JUN, gave an average 40% tumor reduction in H841 xenografts. Scaled 25-fold with a MaxCyte GTx electroporator, three donors yielded 1.2–3.5 × 10^9 CAR+ T cells by day 14, with mon…
Publications
Other
G-Rex®24 Well Plate
Publication Date: January 12, 2026
A xeno-free, feeder-free protocol converts clinical-grade HLA-homozygous human iPSCs into functional macrophages, combining 3D embryoid body agitation in the early stages with G-Rex® plates for the final stages. Three iPSC lines were differentiated over 31 days through mesoderm, hematopoietic, myeloid and macrophage stages. A single embryoid body seeded with 25×10³ CD34+ cells in 6-well plates under rotation gave the best myeloid progenitor yield. In the progenitor-to-macrophage step, 24-well G-Rex® plates allowed a similar yield at a tenfold higher seeding density than standard plates, and three M-CSF spikes increased output. The macrophages expressed CD14, CD86 and CD206 in 98% of cells…
Publications
NKT Cells
G-Rex®24 Well Plate
Publication Date: January 10, 2026
Co-expressing IL-18 in GD2-targeted CAR-NKT cells improved their antitumor function in neuroblastoma models and reprogrammed their metabolism, whereas adding IL-15 to IL-18 caused lethal toxicity in mice. In repeat tumor challenge assays, IL-18-expressing CAR-NKTs killed more tumor cells, proliferated more and secreted more IFN-γ, TNF-α and GM-CSF than IL-15-only cells. In NSG mice with metastatic CHLA255 neuroblastoma, IL-18 CAR-NKTs controlled tumors better than IL-15 cells and extended survival without weight loss, and results were reproduced in a CHLA136 model. Mice given IL-15/IL-18 cells lost weight, even at a reduced dose, but rimiducid reversed this. Bulk and single-cell RNA-seq a…
No manuscripts match your filters.